Bicara Therapeutics Inc
BCAX15.980USD
-0.270-1.66%
收盤 11/03, 16:00（美東）報價延遲15分鐘
871.81M總市值
虧損本益比TTM
關於 Bicara Therapeutics Inc 公司
Bicara Therapeutics Inc. 是一家臨牀階段的生物製藥公司，致力於爲實體瘤患者提供變革性的雙功能療法。其主要項目 ficerafusp alfa 是一種雙功能抗體，結合了兩個經過臨牀驗證的靶點，即表皮生長因子受體 (EGFR)，定向單克隆抗體與與人轉化生長因子β (TGF-b) 結合的結構域。通過這種雙重靶向機制，ficerafusp alfa 有可能通過同時阻斷癌細胞內在的 EGFR 存活和增殖以及腫瘤微環境中的免疫抑制 TGF-b 信號傳導來發揮強大的抗腫瘤活性。ficerafusp alfa 最初是在頭頸部鱗狀細胞癌中開發的，該領域仍存在大量未滿足的需求。其平臺旨在促進雙功能療法的開發，這些療法可精確靶向腫瘤並將調節腫瘤的有效載荷遞送到腫瘤部位。
Bicara Therapeutics Inc簡介
公司代碼BCAX
公司名稱Bicara Therapeutics Inc
上市日期Sep 13, 2024
CEODr. Claire Mazumdar, Ph.D.
員工數量55
證券類型Ordinary Share
年結日Sep 13
公司地址116 Huntington Avenue, Suite 703
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02116
電話16174684219
網址https://www.bicara.com/
公司代碼BCAX
上市日期Sep 13, 2024
CEODr. Claire Mazumdar, Ph.D.
Bicara Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
309.89K
--
Dr. Ryan Cohlhepp, Pharm.D.
Dr. Ryan Cohlhepp, Pharm.D.
President, Chief Operating Officer
President, Chief Operating Officer
198.14K
-10.40%
Mr. Ivan Hyep
Mr. Ivan Hyep
Chief Financial Officer
Chief Financial Officer
145.35K
--
Dr. Nils Lonberg, Ph.D.
Dr. Nils Lonberg, Ph.D.
Independent Director
Independent Director
29.99K
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
--
--
Dr. David Raben, M.D.
Dr. David Raben, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Vijay Kuchroo, Ph.D.
Dr. Vijay Kuchroo, Ph.D.
Independent Director
Independent Director
--
--
Dr. Kiran Mazumdar Shaw
Dr. Kiran Mazumdar Shaw
Independent Director
Independent Director
--
--
Mr. Scott Robertson
Mr. Scott Robertson
Independent Director
Independent Director
--
--
Ms. Kate Haviland
Ms. Kate Haviland
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
309.89K
--
Dr. Ryan Cohlhepp, Pharm.D.
Dr. Ryan Cohlhepp, Pharm.D.
President, Chief Operating Officer
President, Chief Operating Officer
198.14K
-10.40%
Mr. Ivan Hyep
Mr. Ivan Hyep
Chief Financial Officer
Chief Financial Officer
145.35K
--
Dr. Nils Lonberg, Ph.D.
Dr. Nils Lonberg, Ph.D.
Independent Director
Independent Director
29.99K
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
--
--
Dr. David Raben, M.D.
Dr. David Raben, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
12.75%
Biocon Ltd.
10.12%
Invus Public Equities Advisors, LLC
9.56%
Vestal Point Capital, LP
9.16%
Red Tree Management, LLC
5.81%
其他
52.59%
持股股東
持股股東
佔比
RA Capital Management, LP
12.75%
Biocon Ltd.
10.12%
Invus Public Equities Advisors, LLC
9.56%
Vestal Point Capital, LP
9.16%
Red Tree Management, LLC
5.81%
其他
52.59%
股東類型
持股股東
佔比
Investment Advisor
38.31%
Investment Advisor/Hedge Fund
19.20%
Venture Capital
17.76%
Corporation
10.77%
Hedge Fund
10.22%
Private Equity
7.26%
Research Firm
1.44%
Individual Investor
1.42%
Pension Fund
0.16%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
204
51.57M
94.51%
-222.49K
2025Q2
189
57.62M
105.65%
+8.16M
2025Q1
183
53.15M
97.51%
+4.06M
2024Q4
149
51.31M
94.30%
+11.56M
2024Q3
80
39.83M
80.65%
+39.83M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
6.96M
12.75%
--
--
Jun 30, 2025
Biocon Ltd.
5.52M
10.12%
+5.41M
+4671.98%
Apr 14, 2025
Invus Public Equities Advisors, LLC
5.22M
9.56%
+1.95M
+59.68%
Jun 30, 2025
Vestal Point Capital, LP
5.00M
9.16%
+2.23M
+80.57%
Jun 30, 2025
Red Tree Management, LLC
3.17M
5.81%
--
--
Jun 30, 2025
TPG Capital, L.P.
3.01M
5.52%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
2.54M
4.65%
-1.07M
-29.71%
Jun 30, 2025
Deep Track Capital LP
2.43M
4.45%
+426.66K
+21.33%
Jun 30, 2025
Omega Fund Management, LLC
2.20M
4.04%
--
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
2.12M
3.88%
+344.02K
+19.41%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
ALPS Medical Breakthroughs ETF
0.51%
Hypatia Women CEO ETF
0.25%
Fidelity Enhanced Small Cap ETF
0.06%
T Rowe Price Small-Mid Cap ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.02%
Global X Russell 2000 ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.98%
ALPS Medical Breakthroughs ETF
佔比0.51%
Hypatia Women CEO ETF
佔比0.25%
Fidelity Enhanced Small Cap ETF
佔比0.06%
T Rowe Price Small-Mid Cap ETF
佔比0.05%
iShares Russell 2000 Value ETF
佔比0.04%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0.03%
ProShares Hedge Replication ETF
佔比0.02%
iShares Russell 2000 ETF
佔比0.02%
Global X Russell 2000 ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
